Warning: Use of undefined constant php - assumed 'php' (this will throw an Error in a future version of PHP) in /home/onemedpl/public_html/database/comp_profile_include.php on line 64
Biotech Specialty Pharma

Tolera Therapeutics

350 E. Michigan Avenue, Suite 205
Kalamazoo, MI 49007 USA

Warning: Use of undefined constant php - assumed 'php' (this will throw an Error in a future version of PHP) in /home/onemedpl/public_html/database/comp_profile_include.php on line 92
Click for website

Research Sector Biotech Specialty Pharma

Summary Description T-Cell Modulation for Treatment of Autoimmune Disorders, Transplant

Management John J. Puisis, President and CEO; Maria Siemionow, MD, PhD, DSc, CSO; Jim Herrmann, Chief Operating Officer

Click here for Financial Data
Keywords: Phase 2, monoclonal antibody, immunology, transplant, T-cell therapy, TCR, induction, autoimmune, diabetes, multiple sclerosis, Oncology


Updated: Sept. 17, 2013


Tolera offers a highly specific T-cell targeting monoclonal antibody technology (anti- TCR) with broad application potential in T-cell mediated disease such as transplant rejection, autoimmune disea......view more

Products / Services

Tolera has a clinically proven, T-cell specific, monoclonal antibody, in Phase 2 trials (TOL101). It has been successfully manufactured and purified to GMP standards for clinical investigation and com......view more

Technology / Differentiation

Current T-cell antagonists operate as either overly broad spectrum, toxic agents, or as overly specific and less effective immune inhibitors. As a result, clinicians are seeking safer alternatives for...view more

Market / Customers

The initial target market will be the solid organ transplant market where the MAb and its humanized versions have an attractive product profile for T-cell modulation. Other potential indications to b......view more

Competitors / Substitutes / Alternatives

No other targeted anti-TCR drugs are approved, or under investigation for human therapeutic use....view more


Develop safer, more targeted, T-cell therapy: TOL101. Obtain FDA market approval for first indication (solid organ transplant) within 3 years. Partner with a collaborator to parallel track development...view more

Revenue / Funding

Currently venture funded, "Series B". A follow-on investment opportunity is currently open (Dec 2010 - March 2011) for opportunistic investment....view more


Tolera was granted orphan drug status for solid organ transplantation in April 2009 and for type 1 diabetes in 2010. The company's product has been in previous human studies, and is ready for later s...view more


    Fatal error: Uncaught Error: Call to undefined function mysql_connect() in /home/onemedpl/public_html/include/counter.php:10 Stack trace: #0 /home/onemedpl/public_html/database/comp_profile_include.php(1079): include() #1 /home/onemedpl/public_html/database/comp_profile.php(87): include('/home/onemedpl/...') #2 {main} thrown in /home/onemedpl/public_html/include/counter.php on line 10